Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States
184 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors
10/22/2018
Dr. Hege brings more than 20 years of oncology clinical leadership experience to Arcus’s board.
-
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
-
Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress
10/8/2018
Arcus Biosciences, Inc. today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany.
-
Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates
8/6/2018
Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in the first half of 2019
-
Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference
8/1/2018
Arcus Biosciences, Inc. will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY.
-
Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody
7/30/2018
Arcus Biosciences, Inc. announced that it has received regulatory approval to initiate its Phase 1 trial for AB154
-
Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers
7/17/2018
AB928 was safe and well tolerated at all doses evaluated
-
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
7/12/2018
Arcus Biosciences, Inc. announced that Taiho Pharmaceutical Co., Ltd. exercised its option under the Option and License Agreement entered into in September 2017 (Taiho Agreement) to obtain an exclusive development and commercialization license to the Company’s adenosine receptor antagonist program
-
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer
6/12/2018
Ms. Jarrett will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources.
-
Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations
6/11/2018
Phase 1/1b trial to evaluate the safety, tolerability and preliminary efficacy in patients with breast and gynecologic malignancies.
-
Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting
4/17/2018
CEO "extremely encouraged by the results from our ongoing Phase 1 trial of AB928."
-
Arcus Biosciences Announces Five Abstracts Accepted for Presentation at AACR 2018 Annual Meeting
3/15/2018
Arcus Biosciences announced that five abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, Illinois.
-
Arcus Biosciences Announces Pricing of Initial Public Offering
3/14/2018
Arcus Biosciences announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15.00 per share for total gross proceeds of $120,000,000.
-
Arcus Biosciences Appoints David Beier to Board of Directors
12/18/2017
Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization.
-
Sage Therapeutics Fills Its Pockets
11/27/2017
Sage Therapeutics has been on a roll with good news lately. -
Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing.
-
Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma
9/21/2017
-
Arcus Biosciences Appoints Kate Falberg To Its Board Of Directors
9/18/2017
-
Arcus Biosciences, Wuxi Biologics Hammer Out R&D Cancer Pact Worth $816 Million+
8/17/2017